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Chimeras of Bet v 1 and Api g 1 reveal heterogeneous IgE
responses in patients with birch pollen allergy
Barbara Gepp, MSc,a Nina Lengger,a Merima Bublin, PhD,a Wolfgang Hemmer, PhD,b Heimo Breiteneder, PhD,a and
Christian Radauer, PhDa Vienna, AustriaBackground: Characterization of IgE-binding epitopes of
allergens and determination of their patient-specific relevance is
crucial for the diagnosis and treatment of allergy.
Objective: We sought to assess the contribution of specific
surface areas of the major birch pollen allergen Bet v 1.0101 to
binding IgE of individual patients.
Methods: Four distinct areas of Bet v 1 representing in total
81% of its surface were grafted onto the scaffold of its homolog,
Api g 1.0101, to yield the chimeras Api-Bet-1 to Api-Bet-4. The
chimeras were expressed in Escherichia coli and purified. IgE
binding of 64 sera from Bet v 1–sensitized subjects with birch
pollen allergy was determined by using direct ELISA.
Specificity was assessed by means of inhibition ELISA.
Results: rApi g 1.0101, Api-Bet-1, Api-Bet-2, Api-Bet-3, and
Api-Bet-4 bound IgE from 44%, 89%, 80%, 78%, and 48% of
the patients, respectively. By comparing the amount of IgE
binding to the chimeras and to rApi g 1.0101, 81%, 70%, 75%,
and 45% of the patients showed significantly enhanced IgE
binding to Api-Bet-1, Api-Bet-2, Api-Bet-3, and Api-Bet-4,
respectively. The minority (8%) of the sera revealed enhanced
IgE binding exclusively to a single chimera, whereas 31%
showed increased IgE binding to all 4 chimeras compared with
rApi g 1.0101. The chimeras inhibited up to 70% of IgE binding
to rBet v 1.0101, confirming the specific IgE recognition of the
grafted regions.
Conclusion: The Bet v 1–specific IgE response is polyclonal,
and epitopes are spread across the entire Bet v 1 surface.
Furthermore, the IgE recognition profile of Bet v 1 is
highly patient specific. (JAllergyClin Immunol 2014;134:188-94.)
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repertoire, chimera-based technology, IgE epitope mapping, birch
pollen allergy
Birch is one of the main elicitors of pollinosis in Europe.1 More
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Open access under CC BY license.Finland, and Sweden are sensitized to the major birch pollen
allergen Bet v 1,2 which belongs to the pathogenesis-related 10
family of plant pathogenesis-related proteins.3 Additionally,
more than 70% of patients with birch pollen allergy have
adverse reactions to certain plant foods.4 This cross-reactivity is
caused by sensitization to Bet v 1 and binding of Bet v 1–specific
IgE to homologous plant food allergens. Bet v 1–related proteins
have been identified as major allergens in apple (Mal d 1), cele-
ry (Api g 1), cherry (Pru av 1), and carrot (Dau c 1), among
others.5-8
Until now, little has been known about the nature of IgE-
binding epitopes of Bet v 1 and related plant food allergens.
Epitope mapping is crucial to understand immune responses to
allergens and allergen cross-reactivity among homologous pro-
teins. Furthermore, knowledge about pivotal IgE-binding re-
gions provides the basic information required for the design of
safe and effective reagents used for allergen-specific immuno-
therapy, the only curative and specific approach in the treatment
of allergy.9
It was shown that IgE binding to Bet v 1 was highly
dependent on the protein’s native conformation.10,11 Thus the
analysis of IgE-binding epitopes of Bet v 1 represents a chal-
lenging task. Thus far, only 1 epitope was indirectly determined
by means of the cocrystallization of Bet v 1.0112 and the Fab
fragment of a murine mAb capable of blocking IgE binding
to Bet v 1 by 40%.11 This epitope covered the P-loop, a highly
conserved region among pathogenesis-related 10 family mem-
bers.12 Furthermore, the contribution of the P-loop to IgE bind-
ing of Bet v 1 was proved by means of site-directed mutagenesis
of Bet v 1 and Pru av 1. Exchange of Glu45 in both proteins
reduced IgE binding for most patients’ sera.13,14 The existence
of high and low IgE binding isoallergens of Bet v 1 and the gen-
eration of hypoallergenic mutants led to the definition of further
key residues important for IgE binding to Bet v 1 and Mal
d 1.15-17 Another strategy to identify epitopes is based on
mimicking the epitope in its interaction with IgE by short pep-
tides selected from random-peptide libraries. This so-called
mimotope technology was applied to identify preferred IgE-
binding regions of Bet v 1.18,19 Engineering of chimeric pro-
teins of Bet v 1 and homologous proteins represents a further
approach for investigating B-cell epitopes. By using epitope
grafting, 3 IgE-binding regions important for cross-reactivity
between Bet v 1 and Mal d 1 were examined.20-22
Because the diversity of the IgE response to Bet v 1 among
individual patients with birch pollen allergy has never been
investigated in detail, we aimed to determine the patient-specific
IgE recognition profile of a large group of patients. We generated
4 chimeras of Bet v 1.0101 and its low-allergenic, nonsensitizing
homolog Api g 1.0101 from celeriac.23-25 On the basis of the
known crystal structures of Bet v 126 and Api g 1,27 4 selected
Bet v 1–specific portions covering the major part of the molecular
surface were grafted onto the Api g 1 scaffold.
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Patients and control subjects
In a retrospective study 64 residual serum samples of Austrian Bet v
1–sensitized patients with birch pollen allergy drawn during routine diagnosis
at the Floridsdorfer Allergiezentrum, Vienna, Austria, were included
(see Table E1 in this article’s Online Repository at www.jacionline.org).
The patients underwent no interventions related to the study. The use of
anonymized serum samples and clinical records without obtaining written
consent of the patients was approved by the ethics committee of the Medical
University of Vienna (approval no. 718/2010).
Patients were selected on the basis of a typical case history of birch pollen
allergy, positive skin prick test responses to birch pollen, and/or in vitro IgE
detection to rBet v 1 or birch pollen extract (>_0.35 kUA/L; ImmunoCAP,
Thermo-Fisher, Uppsala, Sweden). The average age of the patients was 34
years (range, 7-79 years). The sex distribution was balanced, with 56% female
and 44%male patients. History of food allergy to common birch pollen–asso-
ciated plant foods was assessed based on questioning by an experienced aller-
gist. Fifty-two percent (n5 33) had allergic symptoms after ingestion of plant
foods, with a single patient reporting celery allergy. Twenty-two percent (n5
14) did not report food allergies, and for the rest (n5 17), these data were not
available. As a negative control, sera from 7 nonallergic patients without his-
tories of type I allergy to common allergen sources were included.
Design of the Api g 1–Bet v 1 chimeras
Chimeric proteins of Bet v 1.0101 and its homolog Api g 1.0101 were
generated to investigate IgE binding to defined Bet v 1.0101–specific surface
areas. Grafting of Bet v 1–specific surface areas onto the Api g 1.0101 scaffold
was achieved by replacing Api g 1.0101–specific solvent-accessible (>20%)
residues by corresponding Bet v 1.0101–specific residues (Fig 1).We generated
the chimeric protein Api-Bet-1 by grafting Glu45, the central residue of the pre-
viously identified P-loop epitope, and surrounding residues, identified by using
UCSF Chimera,28 onto Api g 1.0101. The region opposite the P-loop (Api-Bet-
2), the C-terminus and surrounding residues (Api-Bet-3), and the C-terminal a-
helix (Api-Bet-4) of Bet v 1.0101 were grafted in the same manner to generate
spatially well-distributed Bet v 1.0101–specific surface areas on Api g 1.0101.
Cloning, expression and purification, and
physicochemical analysis of the recombinant
proteins
Production and analysis of the recombinant proteins was performed as
described in the Methods section in this article’s Online Repository at www.
jacionline.org.
IgE ELISA
For direct ELISA, microtiter plates (Maxisorp; Nalge Nunc International,
Roskilde, Denmark) were coated overnight at 48C with 1 mg/mL individual
chimeric proteins, a mixture of all chimeras (1 mg/mL each), and rApi g
1.0101 or rBet v 1.0101, respectively, in 50 mmol/L sodium carbonate buffer,
pH 9.6. After blocking of nonspecific binding sites, sera (1:10 dilution) were
incubated in duplicates overnight at 48C. Specific IgEwas detected by using an
alkaline phosphatase–conjugated mouse anti-human IgE mAb (BD Pharmin-
gen, San Jose, Calif), followed by color development with Sigma FAST
p-nitrophenyl phosphate tablets (Sigma-Aldrich, St Louis, Mo) and measure-
ment of the absorbance at 405 nm.
OD values were measured at several time points. For each serum, the
measurement with an OD of approximately 1.0 for Bet v 1.0101 was
normalized to a 1-hour substrate incubation period after subtracting the OD
values of the buffer controls (see Table E2 in this article’s Online Repository at
www.jacionline.org). Comparison of measurements at different times proved
that the OD values increased with time in a linear fashion (data not shown).
Hence normalized OD values were roughly proportional to allergen-specific
IgE concentrations.
Individual sera from 7 nonallergic donors were included as negative
controls. Normalized OD values exceeding themean negative control value by
more than 3 SDs were considered positive.For each serum, specific IgE binding to the grafted regions of each chimera
was assessed by calculating the difference of the OD values of the chimera and
rApi g 1.0101. The difference was considered positive if it exceeded 3 times
the SD of the negative control value.
ELISA inhibition
For inhibition ELISA, coating, blocking, and detection were performed, as
described above. Either Bet v 1.0101 or the chimeras were coated to the solid
phase. In inhibition assays, in which rBet v 1.0101 was coated, IgG was
removed in advance by means of incubation of prediluted sera on an anti-
human IgG (BD Pharmingen)–coated plate. Sera were diluted 30- to 100-fold.
Inhibition was performed by preincubating diluted sera with 10-fold serial
dilutions from 0.01 to 100 mg/mL of the individual chimeric proteins, a
mixture of all chimeras, and rApi g 1.0101 or rBet v 1.0101, respectively,
before they were applied to the plates.
For cross-inhibition between the chimeras, all chimeras, rApi g 1.0101, and
rBet v 1.0101 (1 mg/mL) were coated to the solid phase and incubated with
patients’ sera (diluted 10- to 60-fold). The supernatants were transferred to a
second plate, which was coated with all 4 chimeras or buffer only. IgE binding
to the second plate was detected, as described above.
Inhibition values were calculated as follows:
Inhibition ½%5 ð12ODinhibited=ODnoninhibitedÞ3100:
ELISA with Bet v 1–specific mAbs
Binding of Bet v 1–specific mAbs to rBet v 1, rApi g 1, and the chimeras
was tested by usingELISA, as described in theMethods section in this article’s
Online Repository.
Statistical analyses
The Friedman test (a5 .05) was performed to test whether the amount of
IgE binding to each of the 4 chimeras differed significantly from that to rApi g
1.0101. The relationship between the number of chimeras recognized better
than rApi g 1.0101 and the amount of rBet v 1–specific IgE present in patients’
sera was analyzed by performing Spearman correlation (a 5 .05).
RESULTS
Biochemical characterization of the recombinant
proteins
The structural integrity of the recombinant proteins was
confirmed by means of circular dichroism spectroscopy, mass
spectrometry, and ELISA with Bet v 1–specific mAbs, as
described in the Results section in this article’s Online Repository
at www.jacionline.org.
IgE-binding profiles of Bet v 1 are highly patient
specific
IgE-binding capacities of rBet v 1.0101, rApi g 1.0101, and the
chimeras were determined by means of ELISA. All 64 tested sera
displayed rBet v 1–specific IgE, whereas only 44% of the sera
bound to rApi g 1 (Table I). Total IgE-binding capacities of all 4
chimeras were significantly higher than that of rApi g 1 (P <.001;
median OD for rApi g 1, 0.028; median ODs for the chimeras,
0.076-0.222; see Fig E3 in this article’s Online Repository at
www.jacionline.org).
For each serum, specific IgE binding to the grafted regions of
each chimera was assessed by calculating the difference of the
ELISAOD values of the chimera and the template rApi g 1.0101.
The grafted regions of Api-Bet-1, Api-Bet-2, and Api-Bet-3 were
recognized by 70% to 81% of the sera, whereas only 45%
recognized Api-Bet-4 (Table I).
Patients were categorized according to their binding patterns to
evaluate individual IgE recognition profiles (Fig 2). Interestingly,
FIG 1. Sequence and structural comparison of the chimeras. A, Front and back views (rotated by 1808
around a vertical axis) of the parent molecules and the chimeras are depicted. Colors indicating
mutated residues were mapped onto the Api g 1 surface. The models were prepared with UCSF Chimera.28
B, Multiple sequence alignment of proteins.
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of a single chimeric protein. Furthermore, 19 and 17 (30% and
27%, respectively) sera showed increased IgE binding to 2 or 3
chimeras, respectively, compared with rApi g 1.0101. The highest
number of patients possessed IgE directed to all 4 grafted regions
(20/64 [31%]). Only 3 (5%) sera did not bind to any grafted region.Inhibition ELISA confirms IgE specificity for the
grafted areas
Data of 4 representative sera are depicted in Fig 3. Direct ELISA
data (Fig 3, A) show the highly patient-specific IgE-bindingpatterns to the chimeric proteins. The percentage of Bet v
1–specific IgE that bound to the chimeras was tested by using an
inhibition ELISA (Fig 3, B) in which rBet v 1.0101 was coated
to the solid phase. Self-inhibition of rBet v 1.0101 was complete
at inhibitor concentrations of 10 mg/mL. In most cases the chi-
meras did not reach saturating inhibition, even at 100 mg/mL.
Maximum inhibition values ranged from 7% to 71%, depending
on the serum and the inhibitor protein. A mixture of all 4 chimeras
inhibited IgE binding to Bet v 1 by 55% to 77%. In contrast,
rApi g 1 inhibited IgE binding to rBet v 1 by only 2% to 27%.
The 4 chimeras were coated to the solid phase to examine the
percentage of chimera-specific IgE that bound to the grafted areas
TABLE I. Frequencies of IgE binding among patients with birch
pollen allergy (n 5 64) to rBet v 1, rApi g 1, and the chimeras
determined by means of ELISA
Frequencies of recognition
Frequencies of IgE binding
to grafted regions*
rBet v 1 100% 100%





*Percentage of patients with IgE binding significantly increased compared with
rApi g 1.
FIG 2. Patient-specific patterns of IgE binding to the grafted regions of
chimeric proteins. IgE binding of Bet v 1–sensitized patients’ sera (n 5 64)
was determined bymeans of IgE ELISA. The OD values obtainedwith rApi g
1 were subtracted, and significantly positive values were counted.
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1.0101, and the immobilized chimeras. In all cases almost com-
plete inhibition of IgE binding to the chimeras by rBet v 1.0101
was observed. The extent to which rApi g 1.0101 inhibited IgE
binding to the chimeras showed large differences between the
tested sera. Inhibitions with 3 sera (4, 20, and 31) yielded percent-
ages between 10% and 68%, with the exception of a single high
value. In contrast, inhibitions with serum 2 resulted in high ex-
tents of inhibition (82% to 91%) for all 4 chimeras, indicating
low percentages of IgE binding to the grafted areas.
Furthermore, ELISA inhibitions were performed in which IgE
binding to each chimera was inhibited by all other chimeras (see
Fig E5, B, in this article’s Online Repository at www.jacionline.
org). We observed partial cross-reactivity between Api-Bet-1
and Api-Bet-4, as well as between Api-Bet-2 and Api-Bet-3,
for some sera.The amount of Bet v 1–specific IgE correlates with
the number of chimeras recognized
The number of chimeras to which IgE binding to the grafted
region was detected and the amount of Bet v 1–specific IgE in
patients’ sera showed a significant correlation (r5 0.35, P5 .01;
see Fig E4 in this article’s Online Repository at www.jacionline.
org). Comparing the OD values of the Bet v 1–specific IgE ELISA
after 1 hour yielded a median OD of 1.03 for sera that recognized
no chimeras, whereas this value was 1.98 and 2.39 for sera bind-
ing to 3 or all 4 chimeras, respectively.DISCUSSION
Thus far, little is known about the distribution of IgE-binding
epitopes on the surface of the major birch pollen allergen Bet v 1.
We grafted defined Bet v 1 surface areas onto the structurally
homologous celery allergen Api g 1.0101, which has a much
lower capacity to bind IgE from patients with birch pollen allergy.
We then used these chimeric proteins to analyze IgE binding to
the grafted areas for a large group of patients with birch pollen
allergy. A similar approach was used to investigate IgE binding to
the P-loop20 and other relevant single amino acid residues of Bet v
121,22 or other allergens.29-31 However, we are the first to analyze
IgE binding to a large portion of the solvent-exposed surface area
of Bet v 1.0101.
The combined mutated residues of all 4 chimeric allergens,
including residues conserved between Bet v 1.0101 and Api g
1.0101, comprised more than 80% of the molecular surface of Bet
v 1.0101. To obtain reliable data, we ensured that the recombinant
proteins folded correctly. We checked the secondary structures of
the chimeras using circular dichroism spectroscopy and obtained
spectra highly similar to that of rApi g 1 (see Fig E1, A, in this ar-
ticle’s Online Repository at www.jacionline.org). Furthermore,
we performed an ELISAwith 2 Bet v 1–specific mAbs that bound
to rBet v 1 and Api-Bet-1 but not to the other chimeras and rApi g
1 (see Fig E2 in this article’s Online Repository at www.
jacionline.org). Moreover, a Bet v 1–specific, recombinant, hu-
man single-chain variable antibody fragment (manuscript in prep-
aration) exclusively bound to rBet v 1 and Api-Bet-3. These
experiments proved that Api-Bet-1 and Api-Bet-3 contained sin-
gle Bet v 1–like regions on their surfaces, which were responsible
for their specific antibody-binding abilities. The correct fold of the
chimeras was further substantiated by the fact that the amounts of
IgE binding to all chimeras were equal or greater than the amounts
of rApi g 1–specific IgE in 62 of 64 sera (see Table E3 in this ar-
ticle’s Online Repository at www.jacionline.org).
Several studies aiming to map IgE-binding epitopes on Bet v
1.0101 were performed. The first IgE-binding epitope on Bet v 1
was located by means of crystallization of an antibody-antigen
complex and comprised an area covering the P-loop.11 The
crucial role of this conserved region for IgE binding was
confirmed in several studies.11,20,32 Furthermore, the fact that
an mAb binding to this epitope was able to inhibit specific IgE
binding by approximately 40% supported the concept that a few
epitopes dominated the IgE response to Bet v 1.14
The P-loop of Api g 1.0101 is different because it harbors a
positively charged lysine instead of a negatively charged glutamic
acid at the corresponding position in Bet v 1.0101. We
investigated in detail IgE binding to the P-loop of Bet v 1.0101
by replacing 11 amino acids of Api g 1.0101 by the corresponding
Bet v 1.0101–derived residues (Fig 1). The Api g 1 derivative
generated was termed Api-Bet-1, and 81% of the patients with
birch pollen allergy showed higher IgE binding to this chimera
than to rApi g 1.0101 (Table I). Surprisingly, only 2 of 64 patients
exclusively recognized Api-Bet-1, indicating that the area around
the P-loop is by far not the only region important for IgE binding
to Bet v 1.0101 (Fig 2). This prediction is corroborated by the fact
that, contrary to Api g 1.0101, the isoallergen Api g 1.0201, which
comprises a P-loop similar to Bet v 1.0101,23 has a low
IgE-binding capacity.
In contrast to Bet v 1.0101, Api g 1.0101 has a C-terminus
shortened by 5 residues. In Api-Bet-3 these residues were added
and another 8 amino acids were mutated to obtain a Bet v
FIG 3. ELISA data of 4 representative patients. A, Direct ELISA showing IgE binding to rBet v 1.0101, rApi g
1.0101, the chimeras, and a mix of all chimeras (nonnormalized OD values). B and C, Inhibition of IgE bind-
ing to immobilized rBet v 1.0101 (Fig 3, B) or the chimeras (Fig 3, C) by means of preincubation with rBet v
1.0101 (positive control), rApi g 1.0101, and the chimeras. n.d., Not done.
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decker et al,13 who showed that removing the C-terminal residues
155-159 from Pru av 1.0101 did not affect IgE reactivity, we
observed an increased recognition of Api-Bet-3 compared with
rApi g 1.0101 for 75% of the sera (Table I). Furthermore, Api-
Bet-3 exhibited the highest IgE binding capacity (see Fig E3)
and was able to inhibit IgE binding to rBet v 1 by up to 70%
(Fig 3, B).
For Api-Bet-4, 11 amino acids were mutated in Api g 1.0101 to
create a Bet v 1–specific area around the C-terminal a helix (Fig
1). Compared with the other chimeras, Api-Bet-4 bound the
lowest amount of IgE, and only 45% of the patients showed
enhanced IgE binding to this chimera compared with rApi g
1.0101. In a recent study22 an rBet v 1–specific IgE antibodywas selected from a phage library constructed from IgE-
encoding cDNAs isolated from Bet v 1–sensitized patients. This
antibody bound to the C-terminal helix of Bet v 1, but not to
Mal d 1, which was also proved by grafting the C-terminal helix
of Bet v 1 onto Mal d 1. However, the significance of this epitope
was not tested with patients’ sera.
In our studywe showed that all the chimeras, each of whichwas
bearing a distinct Bet v 1–specific surface area, bound IgE from a
high percentage of patients’ sera. In line with our data, previous
studies showed that the entire surface of a protein is potentially
antigenic.33 Interestingly, 31% of patients with birch pollen al-
lergy recognized all 4 grafted areas, indicating that the immune
response to Bet v 1.0101 is highly polyclonal. Nevertheless, we
observed a total of 12 different recognition profiles in our patient
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(Fig 2).
Consistent with our results, a high patient-to-patient variation
was also observed when investigating IgE binding to the P-loop
mutants of Pru av 1 and Api g 1.0101.13,23,34 Furthermore, Holm
et al20 observed patient-specific IgE repertoires by grafting of a
Bet v 1–specific epitope containing the P-loop onto Mal d 1.
Moreover, IgE binding to various Bet v 1mutants displayed diver-
gent recognition patterns,16,35 and high heterogeneity of IgE spec-
ificity could also be observed by comparing IgE binding to Bet v 1
and homologous food proteins.19 However, most of these studies
were performed with small patient groups.
In a recent study of allergen-specific IgE from patients
sensitized to the major house dust mite allergen Der p 2, it was
shown that the complexity of the allergic patients’ IgE repertoire
correlated with the serum concentration of allergen-specific
IgE.36 In accordance with this finding, we revealed that the
amount of Bet v 1–specific IgE present in patients’ sera correlated
with the number of chimeras recognized, a value representing the
complexity of the IgE epitope repertoire (see Fig E4).
Reduction of IgE cross-linking on the surfaces of mast cells or
basophils by vaccine components during specific immunotherapy
is crucial for preventing severe side effects. Therefore character-
ization of IgE-binding epitopes is of paramount importance for
developing artificial hypoallergens or peptide vaccines for safer
and more effective immunotherapy. Mapping of IgE epitopes by
using a chimera-based approach offers the possibility of
analyzing a defined area (eg, a single IgE epitope) of an allergen
with polyclonal patients’ sera. Thus this technologymight be used
as diagnostic tool to determine the patient-specific response to
defined epitopes of a major allergen or to cross-reactive
homologs. In addition, this will pave the way for a patient-
tailored epitope-based therapy.
Taken together, this study demonstrates that it is possible to
graft defined areas of a major allergen onto a low IgE-binding
homolog to evaluate IgE binding to the grafted region. Further-
more, investigation of a large group of patients with birch pollen
allergy showed that the repertoire of Bet v 1–specific IgE is highly
patient specific and polyclonal. A single major epitope on Bet v
1.0101 important for all patients with birch pollen allergy does
not exist, and relevant IgE-binding epitopes are located across the
entire surface of Bet v 1.0101.
Key messages
d The Bet v 1–specific IgE response is polyclonal, and the
recognition profile is highly patient specific.
d The existence of a single major IgE epitope on Bet v 1 can
be excluded.
d The IgE epitopes are distributed across the entire surface
of Bet v 1.
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